{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:53:23Z","timestamp":1790326403113,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejca.2023.113400","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T23:25:24Z","timestamp":1698449124000},"page":"113400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-0130","authenticated-orcid":false,"given":"David","family":"Malka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Verret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Faron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8344-1762","authenticated-orcid":false,"given":"Rosine","family":"Guimbaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Caramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Galais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le\u00efla","family":"Bengrine-Lefevre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Dupont-Bierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"De Baere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Go\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Dartigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximiliano","family":"Gelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2047-1582","authenticated-orcid":false,"given":"Jean-Pierre","family":"Pignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-7449","authenticated-orcid":false,"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2023.113400_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.113400_bib2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.ctrv.2015.06.006","article-title":"Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus","volume":"41","author":"Adam","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ejca.2023.113400_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2009.23.4450","article-title":"American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer","volume":"28","author":"Wong","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.113400_bib4","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/annonc\/mdv037","article-title":"Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases","volume":"26","author":"de Ba\u00e8re","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113400_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jvir.2017.08.021","article-title":"Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control","volume":"29","author":"Shady","year":"2018","journal-title":"J Vasc Inter Radio"},{"key":"10.1016\/j.ejca.2023.113400_bib6","article-title":"Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): a nationwide prospective intervention study","volume":"3","author":"Osterlund","year":"2021","journal-title":"Lancet Reg Health Eur"},{"issue":"5","key":"10.1016\/j.ejca.2023.113400_bib7","first-page":"969","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"Breedis","year":"1954","journal-title":"Am J Pathol"},{"issue":"41","key":"10.1016\/j.ejca.2023.113400_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027483","article-title":"Comparison between fluoropyrimidine-hepatic arterial infusion and systemic chemotherapy for unresectable liver metastases: a protocol for systematic review and meta-analysis based on 16 observational studies","volume":"100","author":"Zhao","year":"2021","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.ejca.2023.113400_bib9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/SLA.0b013e3181d35983","article-title":"Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases","volume":"251","author":"Go\u00e9r\u00e9","year":"2010","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejca.2023.113400_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1245\/s10434-007-9581-7","article-title":"Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure","volume":"15","author":"Boige","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2023.113400_bib11","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1200\/JCO.2005.05.120","article-title":"Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer","volume":"23","author":"Ducreux","year":"2005","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2023.113400_bib12","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","article-title":"Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma","volume":"27","author":"Kemeny","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2023.113400_bib13","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/annonc\/mdn769","article-title":"Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer","volume":"20","author":"Kemeny","year":"2009","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.113400_bib14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jso.24898","article-title":"Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential","volume":"117","author":"Pak","year":"2018","journal-title":"J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113400_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/SLA.0000000000000614","article-title":"Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes","volume":"261","author":"D\u02bcAngelica","year":"2015","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ejca.2023.113400_bib16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00270-010-9996-6","article-title":"Intra-arterial hepatic chemotherapy: a comparison of percutaneous versus surgical implantation of port-catheters","volume":"34","author":"Deschamps","year":"2011","journal-title":"Cardiovasc Interv Radio"},{"issue":"6","key":"10.1016\/j.ejca.2023.113400_bib17","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/01.cad.0000131684.06390.fe","article-title":"Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model","volume":"15","author":"Dzodic","year":"2004","journal-title":"Anticancer Drugs"},{"issue":"6","key":"10.1016\/j.ejca.2023.113400_bib18","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1245\/s10434-014-4272-7","article-title":"Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases","volume":"22","author":"Allard","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113400_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdv548","article-title":"Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV","volume":"27","author":"L\u00e9vi","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2023.113400_bib20","first-page":"205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"Eur Organ Res Treat Cancer Natl Cancer Inst U S, Natl Cancer Inst Can J Natl Cancer Inst"},{"issue":"14","key":"10.1016\/j.ejca.2023.113400_bib21","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.ejca.2015.06.116","article-title":"Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)","volume":"51","author":"Heinemann","year":"2015","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2023.113400_bib22","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdi246","article-title":"Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates","volume":"16","author":"Folprecht","year":"2005","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.113400_bib23","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2008.19.9273","article-title":"Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?","volume":"27","author":"Adam","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.113400_bib24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/SLA.0b013e31827e9289","article-title":"Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?","volume":"257","author":"Go\u00e9r\u00e9","year":"2013","journal-title":"Ann Surg"},{"issue":"6D","key":"10.1016\/j.ejca.2023.113400_bib25","first-page":"5203","article-title":"Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility","volume":"23","author":"Guthoff","year":"2003","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2023.113400_bib26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.dld.2021.12.012","article-title":"Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +\/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49","volume":"54","author":"Pernot","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"16_suppl","key":"10.1016\/j.ejca.2023.113400_bib27","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1200\/JCO.2023.41.16_suppl.3515","article-title":"Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a multicenter randomized phase II trial (PRODIGE 43 - PACHA-01)","volume":"41","author":"Gelli","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:47Z","timestamp":1760733767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923007025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":27,"alternative-id":["S0959804923007025"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113400","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113400","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113400"}}